Ishibashi, Shun
Brigham and Women's Hospital · Jichi Medical University · University of Cape Town · University of Tennessee Health Science Center · Université de Lille · VA Boston Healthcare System · University of Colorado Anschutz
3 papers on CoChatORCID 0000-0002-1063-1979
Most cited papers
- Verified
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 749
- Verified
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 319
- Verified
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology
Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health
Cited by 140
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free